Treatment of acne with spironolactone: a retrospective review of 395 adult patients at Mayo Clinic, 2007–2017

E. E. Roberts, S. Nowsheen, M. D.P. Davis, M. T. McEvoy, C. C. Newman, J. C. Sartori Valinotti, G. F. Sciallis, R. R. Torgerson, D. A. Wetter

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

Background: Few large studies have assessed spironolactone treatment of adult female acne. Objectives: To explore the role of spironolactone in the treatment of adult female acne. Methods: We performed a retrospective case series assessing the efficacy of spironolactone treatment of a cohort of women evaluated at Mayo Clinic in Rochester, Minnesota, from 2007 through 2017. Results: In total, 395 patients (median age, 32 years) received a median spironolactone dose of 100 mg daily. Approximately two-thirds of patients (66.1%) had a complete response; 85.1% had a complete response or a partial response greater than 50%. Median times to initial response and maximum response were 3 and 5 months. Efficacy was observed across all severity subtypes of acne, including those with papulopustular and nodulocystic acne. Patients received long-term treatment with spironolactone (median duration, 13 months) and had few adverse effects. Conclusions: Spironolactone is a safe and effective treatment of acne for women.

Original languageEnglish (US)
Pages (from-to)2106-2110
Number of pages5
JournalJournal of the European Academy of Dermatology and Venereology
Volume34
Issue number9
DOIs
StatePublished - Sep 1 2020

ASJC Scopus subject areas

  • Dermatology
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Treatment of acne with spironolactone: a retrospective review of 395 adult patients at Mayo Clinic, 2007–2017'. Together they form a unique fingerprint.

Cite this